Double bottom in GILDWonderful double bottom pattern spotted in GILD. It hasn't broken out yet. This chart is for educational purposes only. Please consult your financial advisor before making any buy or sell decision.
4.11EUR
5.13 BEUR
24.51 BEUR
1.25 B
About GILEAD SCIENCES INC.
Sector
Industry
CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Employees (FY)
18 K
Founded
1987
ISIN
US3755581036
FIGI
BBG000DZFX99
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Gildgilead science is in parallel channel since last 6 years and forming bearish downward pattern.
This is not good as follow through for the long pole is missing.
Manage risks and Own profitsHere's a rotated Trade Box For GLD
PLease refere to old trade boxes to get a keymap or feel free to PM!
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where GIS is featured.
Frequently Asked Questions
The current price of GIS is 63.66 EUR — it has decreased by 0.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange GILEAD SCIENCES INC. stocks are traded under the ticker GIS.
GILEAD SCIENCES INC. is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for GILEAD SCIENCES INC. has a max estimate of 113.74 EUR and a min estimate of 64.86 EUR.
GIS earnings for the last quarter are 2.17 EUR whereas the estimation was 1.81 EUR which accounts for 19.50% surprise. Estimated earnings for the next quarter are 1.59 EUR. See more details about GILEAD SCIENCES INC. earnings.
GILEAD SCIENCES INC. revenue for the last quarter amounts to 6.67 B EUR despite the estimated figure of 6.44 B EUR. In the next quarter revenue is expected to reach 6.43 B EUR.
Yes, you can track GILEAD SCIENCES INC. financials in yearly and quarterly reports right on TradingView.
Like other stocks, GIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES INC. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 18.00 K employees. See our rating of the largest employees — is GILEAD SCIENCES INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GILEAD SCIENCES INC. EBITDA is 10.76 B EUR, and current EBITDA margin is 45.96%. See more stats in GILEAD SCIENCES INC. financial statements.